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The primate APOBEC3 gene locus encodes a family
of proteins (APOBEC3A-H) with various antiviral
and antiretroelement activities. Here, we trace the
evolution of APOBEC3H activity in hominoids to
identify a human-specific loss of APOBEC3H antiviral
activity. Reconstruction of the predicted ancestral
human APOBEC3H protein shows that human an-
cestors encoded a stable form of this protein with
potent antiviral activity. Subsequently, the antiviral
activity of APOBEC3H was lost via two polymor-
phisms that are each independently sufficient to
destabilize the protein. Nonetheless, an APOBEC3H
allele that encodes a stably expressed protein is still
maintained at high frequency, primarily in African
populations. This stable APOBEC3H protein has
potent activity against retroviruses and retrotranspo-
sons, including HIV and LINE-1 elements. The sur-
prising finding that APOBEC3H antiviral activity has
been lost in the majority of humans may have impor-
tant consequences for our susceptibility to retroviral
infections as well as ongoing retroelement prolifera-
tion in the human genome.
INTRODUCTION
A substantial fraction of the human genome is comprised of
active and extinct retroelements, a result of numerous germline
insertions by both endogenous retroviruses and non-LTR retro-
transposons (such as LINE and SINE elements) (Lander et al.,
2001). Due to the potentially detrimental effects of the integration
of mobile elements, such as insertional mutagenesis and an
increase in the likelihood of ectopic recombination events (Bois-
sinot et al., 2006), restricting the replication of mobile retroviral
elements by host genes has likely been an ongoing source of
genetic conflict during primate evolution. In particular, primates
have evolved an expanded locus of genes, the APOBEC3
locus, that encodes seven genes in humans (APOBEC3A to
APOBEC3H) that can inhibit retroviruses and retroelements
through cytidine deamination and other mechanisms (MalimCell Hostand Emerman, 2008). The role of APOBEC3 proteins in limiting
the success of retroviral invaders in vivo has been demonstrated
inAPOBEC3/mice with increased susceptibility to the replica-
tion of the mouse retroviral pathogen, mouse mammary tumor
virus (MMTV) (Okeoma et al., 2007).
The human immunodeficiency virus (HIV) can successfully
infect APOBEC3-expressing cells because the virally encoded
Vif protein is able to cause destruction of APOBEC3 proteins
by targeting APOBEC3 proteins to a proteaseome-mediated
degradation pathway (reviewed in Harris and Liddament, 2004;
Malim and Emerman, 2008). Despite efficient inactivation by
HIV Vif, APOBEC3 proteins remain important in vivo because
viruses that no longer encode a functional Vif protein are sensi-
tive to APOBEC3-mediated restriction and bear hallmarks of
hypermutation due to cytidine deamination (Simon et al., 2005).
Genetic conflict between host and pathogen drives rapid
change in interacting host and pathogen proteins (rapid evolu-
tion) as they attempt to increase or decrease interactions with
one another in the battle for dominance. Therefore, a signature
of positive selection is often observed for host proteins that
are directly involved in pathogen defense. APOBEC3G and
APOBEC3H genes, in particular, demonstrate strong signatures
of positive selection in primates that are likely the result of
successive sweeps of APOBEC3 alleles with antiviral activity
against an ever-changing array of rapidly evolving retroviruses
and retroelements (OhAinle et al., 2006; Sawyer et al., 2004).
These signals of adaptive evolution are present throughout
primate phylogeny, suggesting that the conflict of primate
APOBEC3 genes with exogenous retroviruses and endogenous
retroelements is ancient and has taken place over many millions
of years. This ancient conflict has shaped the evolution of a land-
scape of APOBEC3 genes with diverse antiviral functions and
has important implications for the susceptibility of humans to
current retroviral pathogens, such as HIV.
Despite the fact that the APOBEC3H gene is conserved in
mammals and shows positive selection throughout primate
evolution, previous work from our lab and others showed that
whereas rhesusmacaque APOBEC3H is an efficient retroviral in-
hibitor, human APOBEC3H shows little activity against retrovi-
ruses and LINE-1 elements (Dang et al., 2006, 2008; Kinomoto
et al., 2007; Muckenfuss et al., 2006; OhAinle et al., 2006; Virgen
and Hatziioannou, 2007). The lack of antiviral activity of human
APOBEC3H correlates with its low steady-state expression at& Microbe 4, 249–259, September 11, 2008 ª2008 Elsevier Inc. 249
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Human-Specific Loss of APOBEC3H Stabilitythe protein level although mRNA levels between human
APOBEC3H and macaque APOBEC3H are similar (OhAinle
et al., 2006). Moreover, the protein is stable and enzymatically
active in bacteria (OhAinle et al., 2006). Thus, it appears that
humans have lost a functional APOBEC3 gene that has potent
antiviral activity in other primates.
Here, we investigated the evolutionary history of human APO
BEC3H. We found that the stability of the human APOBEC3H
protein was independently lost twice during recent human evolu-
tion through the acquisition of two different amino acidmutations
that decrease the half-life of the protein. Moreover, we recon-
structed the sequence of the human ancestral APOBEC3H
protein and showed that it is well expressed and is very active
against retroviruses and the prolific primate non-LTR retroele-
ment, LINE-1. Despite the presence of two inactivating muta-
tions in APOBEC3H alleles in humans, a sequence survey of
the APOBEC3H alleles from several different human populations
reveals the existence of a stable APOBEC3H allele currently
circulating in the human population. This allele lacks either
destabilizing mutation, is active against LINE-1 elements and
HIV, and is sensitive to the HIV Vif protein. This stable and active
APOBEC3H allele is more prominent in certain world popula-
tions, particularly in African populations, and may reflect local
selective pressures on APOBEC3H alleles across world popula-
tions. Together, these data suggest that our recent human an-
cestors possessed an APOBEC3H allele that was active against
modern retroviruses and retrotransposons but whose function is
now lost in the majority of the human population.
RESULTS
Human APOBEC3H Protein Is Uniquely Unstable
Rhesus macaque APOBEC3H is an efficient inhibitor of retroele-
ments, but human APOBEC3H is not (OhAinle et al., 2006). We
previously showed that the lack of antiviral activity of human
APOBEC3H corresponds with poor steady-state protein expres-
sion (OhAinle et al., 2006). To track the origin of the instability of
the APOBEC3H protein in primate evolution and, therefore, the
likely cause of the loss of antiviral activity, we cloned and ex-
pressed a panel of hominoid APOBEC3H proteins by transient
transfection and evaluated their steady-state expression levels
by western blotting. All hominoid APOBEC3H proteins, except
human, are expressed at levels similar to that of macaque APO
BEC3H (Figure 1A). Importantly, chimpanzee APOBEC3H, the
hominoid APOBEC3H protein with the highest amino acid iden-
tity to human APOBEC3H, is expressed at high levels suggesting
that the stability of human APOBEC3H was lost sometime after
human-chimpanzee speciation. We also cloned and tested the
expression of a second human APOBEC3H allele that differs
from the original human allele at four amino acid sites (R18L,
G105R, K121D, and delN15—amino acid numbering is main-
tained based on the original clone). The expression of the second
human APOBEC3H protein (human_B) is similar to that of the
original human APOBEC3H protein (human_A) and is much
less than that of the chimpanzee APOBEC3H protein (Figure 1B).
To ask if stable expression correlates with antiviral activity, we
tested all the APOBEC3H proteins for inhibition of the mouse
retrotransposon, MusD. All primate APOBEC3H homologs,
except for human, were found to inhibit the replication of MusD
(shown in Figure 1C) as well as other retroviruses and retrotrans-
posons (HIV vif, SIVagm vif, and the L1.3 LINE-1 elements;
data not shown). Thus, the human APOBEC3H protein was
uniquely incapable of inhibiting the retroviruses and retroele-
ments tested.
Figure 1. Instability and Inactivity of APOBEC3H Are Unique to
Humans and Shared between Two Human APOBEC3H Alleles
(A) Western blot analysis of primate APOBEC3H proteins expressed in
transiently transfected 293T cells. Actin is shown as a loading control.
(B) Western blot analysis of chimpanzee and two versions of the human
APOBEC3H protein cloned from two individuals (human_A and human_B).
(C) Inhibition of MusD replication by human APOBEC3G and primate
APOBEC3H homologs. Values are shown as the % retrotransposition relative
to the assay without any APOBEC (No Apobec) expression plasmid. Averages
of three replicates (± SEM) are shown.
(D) Pulse-chase analysis of chimpanzee and both human APOBEC3H proteins
over a 6 hr time course (0, 0.5, 1, 2, and 6 hr). HA-tagged APOBEC3H proteins
were immunoprecipitated and radiolabeled proteins detected at each time
point by autoradiography following SDS-PAGE. An untransfected control
was included to determine background. This is a representative experiment
that was done three times with similar results.
(E) Autoradiography was used to quantitate protein levels at each time point.
Quantities of radiolabeled proteins are shown as the percent of each protein
remaining (% remaining) at that time point relative to time 0 (pulse only). The
stability of the chimpanzee APOBEC3H is shown in the gray line and triangles;
human_A is shown in the solid line and diamonds; human_B is shown in the
solid line and squares. The half-life (t1/2) equal to the time in which 50% of
the APOBEC3H protein remaining for human_A and human_B is marked on
the graph.
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Human-Specific Loss of APOBEC3H StabilityWe then performed a pulse-chase analysis to determine if
the lack of steady-state expression is due to increased protein
turnover. A 30 min pulse with 35S-Cys/Met resulted in approxi-
mately equivalent levels of labeled chimpanzee and human
APOBEC3H proteins, suggesting that equivalent amounts of
both APOBEC3H proteins were synthesized (Figure 1D). How-
ever, both human APOBEC3H proteins showed a dramatic
decrease during the 6 hr chase (Figure 1D). Quantification of
the rate of degradation showed that both human APOBEC3H
proteins have a half-life of less than 30 min, while the chimpan-
zee APOBEC3H protein has a half-life of over 6 hr (Figures 1D
and 1E). Thus, we can attribute the lack of activity of human
APOBEC3H protein to the evolution of a dramatically increased
rate in protein turnover that occurred in the human lineage after
speciation from a common ancestor with chimpanzees.
The C-Terminal Tail of APOBEC3H Contributes
to Subcellular Localization but Is Not the Major
Determinant of Protein Stability
Macaque and human APOBEC3H proteins differ at 31 single
amino acid sites. Further, macaque APOBEC3H encodes a 27
amino acid C-terminal tail that is missing in human and chimp
APOBEC3H due to a Premature Termination Codon (PTC) that
arose in the APOBEC3H coding sequence in the common an-
cestor of human and chimpanzee (Figure 2A). Recently it was
suggested that the PTC may have a role in determining relative
levels of APOBEC3H protein (Dang et al., 2008). However, we
found that while both human and chimpanzee APOBEC3H
alleles encode the PTC, these alleles differ dramatically in the
rate of protein turnover (see Figures 1D and 1E), leading us to
deduce that the PTC is not a major determinant of turnover of
the APOBEC3H protein. We specifically addressed the role of
the C-terminal tail in protein stability and antiviral activity of
APOBEC3H by first deleting the 27-residue C-terminal tail from
the macaque APOBEC3H protein (Macaquetail) and then
fusing the C-terminal tail to the human APOBEC3H protein
(Human+tail). While the tail modifications did result in changes
in expression levels of the proteins (Figure 2B; compare Ma-
caque to Macaquetail and Human to Human+tail), the relative
increase or decrease was not nearly as dramatic as the tail-inde-
pendent differences in expression levels of the human and
chimpanzee proteins (see Figure 1A).
On the other hand, the C-terminal tail did dramatically alter the
subcellular localization of APOBEC3H proteins. Truncation of the
C-terminal tail from macaque APOBEC3H altered its localization
from cytoplasmic to nuclear while addition of the C-terminal tail
to human APOBEC3H altered its localization frommostly nuclear
to mostly cytoplasmic (Figure 2C). It appears that cytoplasmic
localization may be necessary for the antiviral activity of ma-
caque APOBEC3H since truncation of the C-terminal tail impairs
its ability to efficiently restrict HIV-1 (Figure 2D; compare Ma-
caque to Macaquetail). In contrast, the native chimpanzee
APOBEC3H protein lacks the C-terminal tail yet retains robust
antiviral activity (see Figure 1C). More importantly, the human
APOBEC3H chimera with the macaque C-terminal tail does not
restrict HIV-1 (Figure 2D), likely due to a lack of sufficient expres-
sion (see Figure 2B). Although not explored further, we note that
there is a possible Nuclear Export Sequence (NES) in the C-ter-
minal tail that is conserved in other APOBEC family members,Cell Hostsuch as APOBEC1 and AID (Ito et al., 2004) (Figure 2A). Thus,
although the C-terminal tail of primate APOBEC3H appears to
play a role in protein localization, we conclude that the major
determinants of stability of primate APOBEC3H proteins do not
lie within the C-terminal tail.
Figure 2. The C-terminal Tail Controls the Subcellular Localization
but Not the Stability or Antiviral Activity of APOBEC3H
(A) Schematic of the primate APOBEC3H protein. Location of the HAE and
PC–C motifs of APOBEC3H that are conserved in other APOBEC proteins
(Conticello et al., 2005) are shown in black. A Premature Termination Codon
(PTC) truncates human and chimpanzee APOBEC3H homologs by 30 amino
acid residues (asterisk). The leucine residues making up the core of the puta-
tive Nuclear Export Sequence (NES) downstream of the PTC are highlighted in
red in an alignment of human, chimpanzee, gorilla, orangutan, gibbon, and
rhesus macaque APOBEC3H C-terminal tail domains.
(B) Western blot analysis of human, macaque, and chimeric human/macaque
APOBEC3H proteins. Actin is shown as a loading control.
(C) Subcellular localization of human, macaque, and chimeric human/
macaque APOBEC3H proteins in HeLa cells. APOBEC3H proteins were de-
tected with an anti-HA antibody (red) and DAPI staining was used to define
the nucleus (blue).
(D) Inhibition of HIV-1 vif by human, macaque, and chimeric human/
macaque APOBEC3H proteins in a single-cycle infectivity assay. Averages
of triplicate assays (± SEM) are shown as the % Infectivity relative to the
infectivity of HIV in the absence of an APOBEC expression plasmid (No
Apobec).& Microbe 4, 249–259, September 11, 2008 ª2008 Elsevier Inc. 251
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Human-Specific Loss of APOBEC3H StabilityLoss of Stability of Human APOBEC3H Proteins Is due
to Two Independent Mutations
Since the instability and lack of antiviral activity of human
APOBEC3H is not determined by the C-terminal tail, we hypoth-
esized that changes in the APOBEC3H coding sequence must
distinguish human and chimpanzee APOBEC3H orthologs. We
used parsimony to infer those sites in the APOBEC3H coding
sequence that have changed specifically in either the human or
chimpanzee lineages, using the gorilla sequence as an outgroup.
We identified four amino acid changes that have been fixed in the
chimpanzee lineage (upside down black flags in Figure 3A) and
three amino acid changes that have been fixed in humans (short
black flags in Figure 3A). Based on polymorphisms currently seg-
regating in the human population, the human_A protein differs
from chimpanzee APOBEC3H at two additional sites (open flags
in Figure 3A) and human_B differs at three additional sites (gray
flags in Figure 3A). In sum, human and chimpanzee APOBEC3H
proteins differ at 9 and 10 sites, respectively, with some changes
shared in common between both human proteins and other
changes specific to each allele. By creating chimeric proteins
between the chimpanzee APOBEC3H and human APOBEC3H
proteins, we mapped the determinants of the instability of both
human proteins to the N-terminal two-thirds of APOBEC3H (Fig-
ure 3B). Next, we experimentally tested all remaining nonsynon-
ymous changes that distinguish the chimpanzee from the human
APOBEC3H proteins. We found that only reversion of the R105G
polymorphism inhuman_Acould stabilize this protein (Figure 3C).
The fact that the R105G mutation was able to stabilize the hu-
man_A APOBEC3H protein was surprising because this change
is not found in the human_B APOBEC3H protein, suggesting that
an independent change is responsible for its high instability. In-
deed, we found that by reverting the deletion of a single amino
acid residue (delN15), we were able to restore stable expression
of the human_B protein (Figure 3C). In addition, we found that ei-
ther polymorphism (R105G or delN15) is independently sufficient
to destabilize the otherwise stable chimpanzee APOBEC3H
protein (Figure 3D). Thus, remarkably, the human species inde-
pendently lost stable expression of APOBEC3H twice through
different mutations (R105G and delN15) that are each indepen-
dently capable of destabilizing the APOBEC3H protein.
A Stable Human APOBEC3H Protein Inhibits HIV-1
Replication and Is Neutralized by Vif
The mutations that cause the instability of human APOBEC3H
proteins are both polymorphic in the human population. To de-
termine whether or not stable and active alleles of APOBEC3H
might still circulate in the human population, we sequenced the
APOBEC3H coding exons from a panel of individuals from di-
verse world populations (Figure S1). The major haplotypes (set
of polymorphisms that are inherited together on a single chromo-
some) were then inferred using PHASE 2.1.1 software (Table S1)
(Stephens and Donnelly, 2003; Stephens et al., 2001). Four pre-
dicted haplotypes were found at frequencies >10% in our panel
(haplotypes I–IV in Figure 4A and in bold in Table S1. The total
counts for all haplotypes are listed in Tables S2). Amino acid
polymorphisms in haplotypes I–IV are diagramed in Figure 4A.
To ask if any of themajor human APOBEC3H haplotypes iden-
tified in our panel might be stable and active, we reconstructed
the four major haplotypes by site-directed mutagenesis of the252 Cell Host & Microbe 4, 249–259, September 11, 2008 ª2008 Elshuman_A and human_B cDNAs. Three of the four haplotypes
(hap I, hap III, and hap IV) contain one of the destabilizing poly-
morphisms (either R105G or delN15) identified in Figure 3. As ex-
pected, all three haplotypes encoding either of the destabilizing
mutations were found to encode unstable APOBEC3H proteins
(Figure 4B). However, a single human APOBEC3H haplotype
(hap II) encodes an APOBEC3H protein that is as stable as chim-
panzee APOBEC3H (Figure 4B). Therefore, in spite of the two
destabilizing polymorphisms that arose during recent human
evolution, a stable APOBEC3H allele still persists in the human
population.
To ask if the stable human APOBEC3H protein is capable of
retroviral inhibition, APOBEC3H proteins were tested for activity
against both wild-type and vif-deficient HIV-1 (HIV vif). Rhesus
macaqueAPOBEC3H is apotent inhibitor ofHIV-1 and is not neu-
tralized by Vif from HIV-1 but is neutralized by Vif from simian im-
munodeficiency virus (SIV) from african greenmonkeys (SIVagm)
and rhesus macaques (SIVmac) (OhAinle et al., 2006; Virgen and
Hatziioannou, 2007). Consistent with our observed correlation
between stability and antiviral activity of APOBEC3H proteins,
the human APOBEC3H haplotypes that encode unstable pro-
teins have no effect on HIV replication (Figure 4C). In contrast,
both chimpanzee APOBEC3H and the stable humanAPOBEC3H
(hap II) proteins can inhibit HIV-1 (Figure 4C) but areboth counter-
acted by HIV-1 Vif (although to a lesser extent than APOBEC3G)
(Figure 4C; compare white to black bars). Thus, an active form of
APOBEC3H does exist in the human population and, like APO
BEC3FandAPOBEC3G, it is sensitive to inactivation byHIV-1Vif.
Human Ancestors Possessed APOBEC3H Alleles
that Block Retroviruses and LINE-1 Replication
To demonstrate that the loss of stability and antiviral activity of
APOBEC3H occurred specifically during recent human evolu-
tion, we reconstructed and tested the predicted ancestral states
of human APOBEC3H since human-chimpanzee speciation.
Using the gorilla and chimpanzee APOBEC3H sequences as
outgroups to the human APOBEC3H alleles, we constructed
both a hypothetical human ancestor sequence (referred to as
human ancestor) as well as a hypothetical human/chimpanzee
ancestor sequence (referred to as human/chimp ancestor) based
on parsimony (Figure S2). Specifically, human APOBEC3H pro-
tein sequences were aligned with both chimpanzee and gorilla
APOBEC3H. Sites that are polymorphic in humanswere reverted
to the ancestral state, as predicted based on the chimpanzee
sequence, to create the human ancestor APOBEC3H protein.
Similarly, amino acid sites that differ among humans and chim-
panzees were identified and, using the gorilla APOBEC3H
sequence as the outgroup, the ancestral state at each position
was inferred by parsimony.
Next, we used this information to define the evolutionary path
of changes that occurred in the APOBEC3H coding sequence
during recent human evolution (Figure 5A). Four amino acid
changes were fixed in the chimpanzee lineage (black flags in Fig-
ure 5A along the chimp lineage), three nonsynonymous changes
were fixed in the human lineage (black flags in Figure 5A above
‘‘human ancestor’’), and six nonsynonymous changes occurred
in recent human evolution that have not been fixed in the human
population and remain polymorphic in humans (open and gray
flags in Figure 5A). The ancestral APOBEC3H cDNAs (circledevier Inc.
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Human APOBEC3H
(A) Schematic of all nonsynonymous differences (change the encoded amino
acid) between both human (human_A and human_B) and chimpanzee APO-
BEC3H proteins relative to the ancestral amino acid at that position as deter-
mined using gorilla APOBEC3H as the outgroup. The four nonsynonymous
mutations specific to chimpanzee APOBEC3H are shown in upside down
black flags (K16R, K97Q, A142N, and S160C—note that only a single chim-
panzee APOBEC3H was analyzed; therefore, these changes may not neces-
sarily be fixed in the chimpanzee lineage). The three changes fixed in the
human population are shown as the short solid flags (K91E, D158N, and
S160Y). Human APOBEC3H polymorphisms are shown as long flags, open
squares for human_A (R105G and E121K) and long flags, gray squares for hu-
man_B (delN15, R18L, and E121D). Position of the breakpoint of the chimeric
human/chimpanzee APOBEC3H proteins analyzed in (B) is shown as the
dotted line at position 127.
(B) Western blot analysis of native and chimeric human (human_A and hu-
man_B) and chimpanzee APOBEC3H proteins. APOBEC3H expression was
detected with an HA antibody and actin is shown as a control.
(C) Western blot analysis of native and mutant APOBEC3H proteins. Four ofCell Host &nodes in Figure 5A) were then reconstructed in vitro by site-
directed mutagenesis of human and human/chimpanzee
APOBEC3H constructs. Both the human/chimp APOBEC3H
ancestor and the human APOBEC3H ancestor encode stable
APOBEC3H proteins that are expressed at levels similar to that
of the native chimpanzee protein and much higher than those
of the ‘‘unstable’’ human APOBEC3H proteins (Figure 5B). Fur-
ther, both the ancestral APOBEC3H proteins efficiently inhibit
retroviral replication, as indicated by their potent activity against
vif-deficient HIV (Figure 5C, open boxes).
We consistently find that the ancestral versions of APOBEC3H
aremore active than either the extant human (Figure 4C) or chim-
panzee versions of this protein (Figure 5C, open boxes). We also
tested the Vif sensitivity of the reconstructed human/chimp an-
cestor of APOBEC3H and the reconstructed human ancestor
of APOBEC3H. We find that both are at least partially counter-
acted by a modern version of HIV-1 Vif (Figure 5C, solid boxes).
These results suggest that while there has been some degrada-
tion of function of APOBEC3H in both the chimpanzee and the
human lineage, the APOBEC3H protein has still retained a sur-
face that is important for interaction with a modern day HIV-1 Vif.
SinceAPOBEC3H is conserved in eutherianmammals and ap-
pears to have evolved under constant positive selection in pri-
mates (OhAinle et al., 2006), it is likely to have evolved to coun-
teract a more ancient and pervasive pathogen than lentiviruses.
Endogenous retroelements, such as the LINE and SINE non-LTR
retrotransposons, represent such a constant, pervasive threat in
human evolution. Therefore, we tested both modern and ances-
tral human APOBEC3H proteins for the ability to block the repli-
cation of the human LINE-1 element. We find that all stably ex-
pressed APOBEC3H proteins inhibit the replication of LINE-1
(Figure 5D). In contrast, the unstable proteins have no impact
on LINE-1 replication. Similar results were obtained with an Alu
element (data not shown), consistent with previous findings
that APOBEC3G potently blocks Alu transposition (Bogerd
et al., 2006; Hulme et al., 2007). Significantly, the ancestral hu-
man APOBEC3H protein is as good or better than any of the ex-
tant hominoid versions of this gene in terms of its anti-LINE1 ac-
tivity (Figure 6D). Thus, recent human ancestors encoded an
APOBEC3H protein with potent activity against retroviruses
and LINE-1 elements, but this activity now persists in only a frac-
tion of the human population.
Active APOBEC3H Alleles Exist at
Higher Frequency in Individuals
of African Descent
To determine the approximate frequencies of stable and active
alleles across human populations, we genotyped both the inac-
tivating polymorphisms of APOBEC3H (R105G and delN15) in
a larger panel of unrelated individuals from three American pop-
ulations with diverse ancestry, African Americans (AA), European
the five nonsynonymous mutations in the N-terminal region that distinguish
the human_A protein from the chimpanzee protein were mutated in human_A
to match the chimpanzee sequence (x4NS). A single mutation was also ana-
lyzed (G105R). Two single mutations (+N15 and L18R) as well as the double
mutant (+N15/L18R) were analyzed for the human_B protein.
(D) Western blot analysis of native and single mutant chimpanzee APOBEC3H
proteins (chimp R105G/chimp delN15).Microbe 4, 249–259, September 11, 2008 ª2008 Elsevier Inc. 253
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Human-Specific Loss of APOBEC3H StabilityAmericans (EA), and Han Chinese from Los Angeles (CA) (Hinds
et al., 2005). Both destabilizing human polymorphisms are found
at significant frequencies in the populations we sampled (Fig-
ure 6A). Specifically, the N15 deletion is found at relatively similar
frequencies in all three populations (0.27 in African Americans,
0.21 in European Americans, and 0.30 in Han Chinese) (gray
bars in Figure 6A), while R015G differs in frequency among pop-
ulations (0.22 in African Americans, 0.61 in European Americans,
and 0.65 in HanChinese) (black bars in Figure 6A). Pairwise com-
parisons of FST values, a measure of population differentiation
that reflects either demographic effects or regional selection
(Lewontin and Krakauer, 1973), indicate that there is little to no
difference in frequencies of the N15 deletion polymorphism
between the three populations (Figure 6B). In contrast, the
R105G polymorphism is found at significantly higher frequencies
in European Americans andHanChinese as compared to African
Americans (black bars in Figure 6A). The pairwise FST values for
the APOBEC3H R105G single-nucleotide polymorphism (SNP)
are 0.26 and 0.31 for comparisons between African American
and the other two populations, respectively (Figure 6B); these
values are higher than 90% of human SNPs compared in the
same populations in a genome-wide study (Hinds et al., 2005).
Wewere concerned about the potential confounding effects of
admixture in the three populations we had thoroughly analyzed.
Therefore, we examined the incidence of both destabilizing poly-
morphisms in the HapMap dataset that examined a larger panel
of humans, that is relatively devoid of admixture. These included
the Yoruban (YRI) panel from Nigeria, the Caucasian (CEU) panel
of Utah residents with ancestry from northern and western Eu-
rope, and a combined East Asian (JPT/CHN) population that in-
cluded Japanese individuals from Tokyo and Han Chinese indi-
viduals from Beijing (more information about these populations
Figure 4. A Stable and Active Human APOBEC3H
Protein Blocks the Replication of vif HIV
(A) Schematic of the four dominant haplotypes of
APOBEC3H (hap I, hap II, hap III, and hap IV) found in
the human population. Polymorphisms present in each
haplotype are marked with a flag and shading is main-
tained based on the original human_A and human_B
APOBEC3H alleles described in the legend to Figure 3.
Of note, human_A corresponds to haplotype I while
human_B corresponds to haplotype IV except that it lacks
the E178D polymorphism.
(B) Western blot analysis of the four human APOBEC3H
haplotypes and chimpanzee APOBEC3H.
(C) Inhibition of HIV vif by human APOBEC3H proteins
as well as by human APOBEC3G. Single-cycle infectivity
assays were performed for both wild-type (HIV WT) and
vif-deficient HIV (HIV vif) in the presence or absence
of APOBEC expression. Averages of triplicate assays
(± SEM) are shown as % infectivity of the control infection
(No Apobec). Note the log scale on the y axis.
is available from http://www.hapmap.org). We
tabulated the incidences of both the R105G
polymorphism (already typed by the HapMap
consortium) and the N15 deletion. Again, we
found no significant discordance in the inci-
dence of the N15 deletion allele frequencies
across these three populations (Figure 6C). The N15 deletion fre-
quencies ranged from 0.28 to 0.4 with no significant discordance
in allele frequencies (low FST values) between any two popula-
tions. In contrast, we found that the R105G polymorphism ex-
isted at a frequency of 0.689 and 0.608 in the HCB andCEU pop-
ulations, respectively, but only at an incidence of 0.075 in the YRI
population (Figure 6C). This is an even more dramatic discor-
dance in allele frequencies than what we have typed in our
smaller dataset (Figures 6A and 6B). The FST values that highlight
this discordance between African (YRI) and non-African popula-
tions (CEU, HCB) are presented in Figure 6D.
Next we calculated the frequency of the stableAPOBEC3H al-
leles that encode stable proteins in each of the six subpopula-
tions that we had sampled in Figures 6A and 6C. Based on our
phasing analysis, the loci encoding the two destabilizing muta-
tions (R105G and delN15) are tightly linked and, therefore, are
rarely found on the same chromosome (only 2 of 86 chromo-
somes analyzed in our panel are predicted to encode both poly-
morphisms—see Table S2). Therefore, summing the frequencies
of both polymorphismswithin apopulation gives a robust estima-
tion of the frequency of active (stable) versus inactive (unstable)
APOBEC3H alleles in each subpopulation. The relative frequen-
cies of active and inactive APOBEC3H alleles show that the fre-
quency of active APOBEC3H alleles varies significantly between
populations, from 51%–52% in African Americans (AA) and
Yorubans (YRI), 10%–18% in Europeans (CEU) and European
Americans (EUR), and only 3%–4% in East Asian (JPT/CHN)
and Chinese-American populations (Figure 6E). Thus, a gradient
of active APOBEC3H alleles exists with increasing distance from
Africa, from nearly 53% for the African population (YRI), to only
3% for the East Asian population (JPT/CHN) (Figure 6E). There-
fore, the ancestral active APOBEC3H allele has beenmaintained
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LINE-1 Elements
(A) The evolution of modern A3H alleles is presented as a phylogeny of
the human/chimpanzee clade. Four changes (K16R, K97Q, A142N, and
S160C—solid flags) occurred during the evolution of modern chimpanzees.
Three changes (K91E, D158N and S160Y—solid flags) are fixed among human
APOBEC3H alleles. Haplotype I accumulated two further changes (R105G and
E121K—open flags) while haplotypes II–IV are the result of sequential accumu-
lation of four additional changes (E121D and E178D for haplotypes II; plus
del15N for haplotype III; plus R18L for haplotype IV—gray flags). The nodes
representing the human ancestor and the human/chimpanzee ancestor are
circled.
(B) Western blot analysis of human (haplotype I), human ancestor, and human/
chimpanzee ancestor APOBEC3H proteins.
(C) Inhibition of HIV by chimpanzee and ancestral human APOBEC3H proteins.
Averages of triplicate assays (± SEM) are shown as the% infectivity relative to
the control assay with no APOBEC expression (No Apobec). The open boxes
are infections with HIV that contain a deletion in the Vif gene (HIV vif) and the
solid boxes are infections with wild-type HIV that contains a functional Vif gene
(HIV WT). Note the log scale on the y axis.Cell Hostat higher frequency in Africa and has been lost with increasing
distance from Africa.
Remarkably, the trend of loss of APOBEC3H activity in human
populations is similar to that observed for another APOBEC3
gene, APOBEC3B. APOBEC3B is found at a frequency of nearly
100% in African populations but is present in only 40% of East
Asians due to a large structural deletion (Kidd et al., 2007). Since
APOBEC3B and APOBEC3H are present in the same genetic
location, we wished to ascertain whether there was any correla-
tion between the unstable APOBEC3H alleles and the loss of
APOBEC3B. Therefore, we typed the presence or absence of
the APOBEC3B gene in the same individuals from all three sub-
populations (Table S3). We did not find a significant correlation
between nonfunctional alleles of these two genes within individ-
uals (2 by 2 contingency c2 test; p = 0.08). This either means that
the losses of APOBEC3B and APOBEC3H were independent
events or that our test was not powerful enough to identify any
linkage between the two loci. Nevertheless, whether indepen-
dent events or not, populations that lack the APOBEC3B gene,
in particular East Asian populations, are also more likely to
encode inactive APOBEC3H proteins.
DISCUSSION
Wepresent evidence of the evolutionary history ofAPOBEC3H in
humans in which two independent mutations arose during recent
humanevolution andgave rise to anunstableAPOBEC3Hprotein
with no detectable antiviral activity. This is in contrast to our find-
ing of stable expression and antiviral activity of other hominoid
APOBEC3H proteins. Both of the inactivating mutations occur
in distinct regions of APOBEC3H but similarly act to decrease
the half-life of the APOBEC3H protein. Reconstruction of the
ancestral human APOBEC3H gene suggests that recent human
ancestors encoded a very powerful antiretroviral and antire-
troelement version of this gene. While most humans possess
unstable APOBEC3H alleles, we found that a minor fraction of
humans still encode a stable allele ofAPOBEC3H that still retains
activity and can be targeted by the HIV Vif protein.
Our findingof anAPOBEC3H allelewith variable activity among
individuals may have important consequences for the interaction
of the human APOBEC3 locus with HIV. First, in those individuals
homozygous or heterozygous for the active APOBEC3H haplo-
type, there may be an additional APOBEC-mediated block to in-
fection of HIV target cells in addition to the activities of APO-
BEC3F and APOBEC3G. However, we must point out that
although APOBEC3H mRNA is present in the appropriate cell
types (T cells) (OhAinle et al., 2006), it is still unclear if the
APOBEC3H protein is present. Second, our finding that HIV Vif
can inhibit the active APOBEC3H allele argues that HIV Vif may
have specifically evolved to counteract the active APOBEC3H
protein in addition to the other active APOBEC3 proteins. The
mechanism by which HIV Vif recognizes and inhibits APOBEC3H
(D) Inhibition of a human LINE-1 element (L1.3) by chimpanzee, ancestral
human (human ancestor and human/chimp ancestor), and human APOBEC3H
proteins. APOBEC3G and APOBEC3A are shown as a negative and positive
control, respectively. Averages of triplicate assays (± SEM) are shown as the
% infectivity relative to the control assay with no APOBEC expression
(No Apobec).& Microbe 4, 249–259, September 11, 2008 ª2008 Elsevier Inc. 255
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APOBEC3 proteins. Therefore, successful replication of HIV in
individuals with active APOBEC3H alleles may further challenge
Vif evolution even though HIV-1 Vif may be sufficient to counter-
act any potential benefit of active APOBEC3H in humans. Signif-
icant differences in HIV-1 progression have been shown to be
correlated with APOBEC3G variation (An et al., 2004); however,
we do not yet know if individuals heterozygous or homozygous
for active APOBEC3H are more resistant to successful HIV repli-
cation. On the other hand, since the stable APOBEC3H proteins
appear to be able to inhibit multiple retroelements (against both
LINE-1, Alu elements and retroviruses), it is also possible that
APOBEC3H served an ancient role and has no modern impact
on HIV-1.
In light of the multiple protective functions served by
humanAPOBEC3H (against both LINE-1, Alu elements and retro-
viruses), it is puzzling that a majority of humans have lost this
activity and even more puzzling that loss of activity happened
twice in recent human evolution. This suggests the interesting
possibility that nonfunctional APOBEC3H alleles have been
actively selected for in humans. The ‘‘less-is-more’’ hypothesis
Figure 6. Frequency of the Active APOBEC3H Allele Varies
across World Populations
(A) Genotypes were determined for African American (AA; n = 22), Eu-
ropean American (EA; n = 23), and Han Chinese from Los Angeles (CA;
n = 23) for both the R105G (black bars) and N15 deletion (gray bars)
polymorphisms. A list of all inferred haplotypes and their frequencies
is found in Table S1, and a list of the number of individuals with
each haplotype is found in Table S2.
(B) An FST statistic was calculated for both the delN15 and R105G
polymorphisms in pairwise comparisons of each subpopulation (A)
with the other two subpopulations (see Experimental Procedures for
details). FST values near 0 are indicative of no population differentiation
while large FST values suggest either local selection or demographic
effects.
(C) Genotypes from HapMap populations (http://www.hapmap.org)
from Yorubans in Ibadan, Nigeria (YRI; n = 90), Utah residents with an-
cestry from northern and western Europe (CEU; n = 90), and combined
data from Japanese in Tokyo and Han Chinese in Beijing (JPT/CHB;
n = 92) for both the R105G (black bars) and delN15 (gray bars) poly-
morphisms.
(D) An FST statistic was calculated for both the delN15 and R105G
polymorphisms in pairwise comparisons of each subpopulation from
(C) with the other two subpopulations.
(E) Predicted frequencies of APOBEC3H alleles predicted to encode
stable proteins (black sector; that is, with R105 and without the dele-
tion at N15; R105/N15) and unstable proteins (open sectors; that is,
either R105G or the deletion at N15; R105G/delN15) among all six
subpopulations. The % of APOBEC3H alleles predicted to encode
stable proteins is marked to the right of each bar graph.
suggests that loss-of-function mutations can be main-
tained at high frequency during a shift of environmental
pressures under which they may be selectively advanta-
geous, particularly if the functional allele presents a cost
to the host (Olson, 1999). For example, theremay be a sig-
nificant cost associatedwithmaintaining activeAPOBEC3
proteins at high levels in the cell as APOBEC3 proteins
would present a risk to the host if they were to deaminate
the wrong targets, such as cellular mRNA or genomic
DNA. Consistent with this hypothesis, APOBEC3H was
recently shown to hypermutate human papillomavirus, a dou-
ble-stranded DNA virus thought to closely resemble nuclear
DNA (Vartanian et al., 2008). We speculate that APOBEC3H
may be particularly toxic relative to other APOBEC3 family mem-
bers as noduplications of theAPOBEC3H-like domain havebeen
tolerated in any mammalian genome, in striking contrast to the
multiple duplications of the non-APOBEC3H domain (Conticello
et al., 2005; OhAinle et al., 2006). Further, the expression of
APOBEC3H in germline tissues (OhAinle et al., 2006) poses a
mutagenic threat with serious evolutionary consequences and,
therefore, could be particularly costly to the host. In this context,
APOBEC3H may be especially ‘‘costly’’ in humans and chimps,
compared to other primates, because nuclear localization of
the APOBEC3H protein occurred only recently during the evolu-
tion of the protein in hominoids, correspondingwith loss of theC-
terminal domain in the human/chimpanzee ancestor. Therefore,
the nuclear localization and potential risk of increased genomic
DNA editing are greater for humans and chimpanzees than for
other primates. The benefits of maintaining stable and active
APOBEC3H alleles (due to significant selective pressure from
an active exogenous viral infection or from active endogenous
256 Cell Host & Microbe 4, 249–259, September 11, 2008 ª2008 Elsevier Inc.
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ciatedwith the stable APOBEC3Hprotein in chimpanzeesbut not
inhumans. This is plausible given that retroviral infections and ret-
roelement amplifications are known to be distinct among even
these two closely related species (Jern et al., 2006; Polavarapu
et al., 2006; Yohn et al., 2005).
Taken together, our findings suggest that there may be signif-
icant evolutionarypressure todownregulate levels ofAPOBEC3H
protein in the cell in times of decreased pathogenic pressure. Un-
der this scenario, maintaining a stable and active APOBEC3H
protein capable of retroelement inhibition would have to be
balanced with the costs associated with maintaining high
doses of this protein in the cell. Other APOBEC3 proteins that
are localized to the nucleus (and therefore may also contribute
to higher genomic mutation) might also display evidence of this
increased cost. Consistent with this model, APOBEC3B has
also been lost in a significant fraction of human populations
(Kidd et al., 2007), while the start codon of the APOBEC3A
gene ismissing from chimpanzees (unpublished data). These de-
bilitatingevents appear specific to theAPOBEC3genes that have
a nuclear localization, supporting the ‘‘costly defense’’ selective
scenario for the acquisition of destabilizing mutations in human
APOBEC3H.
Nonetheless, thereare importantdifferencesbetween the lossof
APOBEC3B and APOBEC3H activities in humans. While
APOBEC3B has been lost due to a genomic deletion, APO
BEC3H still appears to be expressed but encodes an unstable
protein. We cannot rule out the possibility that instability, rather
than loss of APOBEC3H function, is what has been selected.
Even theunstableAPOBEC3Hallelesmaystill besufficient tocarry
out some antiviral function that we have not assayed. A simple
‘‘loss-of-function’’ hypothesis might be insufficient to explain the
high prevalence of the unstable alleles (50%) even in the African
populations, where APOBEC3H activity still appears to be selec-
tively retained. Instead, our findings suggest that the two unstable
alleles appear to be independently under selection, based on
the discordance in their allele frequencies in different human
populations.
Independent of the true nature of selective pressures shaping
the human APOBEC3 locus, the consequences of these pres-
sures on the antiviral repertoire are significant. Combining the
presence of two ‘‘loss of stability’’ mutations in APOBEC3H
and the loss of the APOBEC3B gene in humans, we can con-
clude that at least two APOBEC3 antiretroviral proteins are
maintained at higher frequencies in African populations and
have subsequently been lost to varying degrees in European
and Asian populations. This is consistent with a model in which
a lower pathogenic burden outside Africamay allow for the accu-
mulation of inactivating mutations in antiviral genes outside of
Africa (either due to genetic drift or due to selection). This implies
both that a relatively recent (and perhaps ongoing) pathogenic
pressure is maintaining APOBEC3H and APOBEC3B activity in
African populations, and further that these populations might
have an associated higher risk of genomic mutations. Regard-
less of the cause, it is clear that much of the redundancy of an
expanded APOBEC3 locus that built up over primate evolution
to defend the genome against the deleterious effects of retro-
transposition or unknown retroviruses has been lost from a
substantial fraction of the human species.Cell HostEXPERIMENTAL PROCEDURES
APOBEC3H cDNA Cloning
APOBEC3H cDNAs were cloned by RT-PCR or nested RT-PCR (QIAGEN
One-Step RT PCR Kit) from RNA derived from chimpanzee (Pan troglodytes
verus—Coriell GM03448), gorilla (gorilla gorilla—Coriell AG05251), orangutan
(Pongo pygmaeus pygmaeus—Coriell AG05252), and gibbon (Nomascus
leucogenys leucogenys—GM051496). Primers used were as follows: chim-
panzee APOBEC3Hwas amplified using an initial round of RT-PCR (50 cycles)
with primers JAK012/JAK015 followed by a second round of 30 cycles (Pfu
Turbo—Stratagene) with primers JAK012/MO136. Gorilla APOBEC3H was
amplified with an initial round of RT-PCR using primers JAK012/JAK015
followed by a second round of 30 cycles with JAK012/MO143. Orangutan
APOBEC3H was amplified in a single round of RT-PCR (50 cycles) using
primers JAK012/MO173. Gibbon APOBEC3H was amplified in a single round
of 50 cycles using primers JAK012/JAK015. RT-PCR products were gel puri-
fied, TOPO cloned (Invitrogen), and sequenced. Cloning of human (= hu-
man_A) and macaque APOBEC3H cDNAs was described previously (OhAinle
et al., 2006). The ‘‘human_B’’ APOBEC3H cDNA was amplified by RT-PCR
from a Druze individual (Coriell #11521) using primers JAK012/JAK015.
Expression Constructs and Plasmids
All APOBEC3H cDNAs were cloned into the XhoI/EcoRI sites of pcDNA3.1 (In-
vitrogen) with a primer-encoded 50 HA tag (MYPYDVPDYA). Chimeric human/
macaque APOBEC3H plasmids were constructed by PCR using primers that
match both themacaque and human APOBEC3H sequences. The Human+tail
plasmid was constructed by PCR using overlapping primers specific for both
the human APOBEC3H C terminus and the macaque APOBEC3H C-terminal
tail domain. First, these primers were used with external primers to create
human APOBEC3H and macaque tail fragments, followed by amplification
with external primers to create the chimeric Human+tail plasmid. The trun-
cated macaque APOBEC3H plasmid (Macaquetail) was constructed by
amplification of macaque APOBEC3H with the human APOBEC3H 30 primer,
resulting in truncation of macaque APOBEC3H at the STOP found in the
human sequence. Chimeric human/chimpanzee constructs were created by
digesting chimpanzee and human APOBEC3H constructs with EcoRI/BamHI
and BamHI/XhoI, purification of plasmid backbone and both fragments, and
triple-ligation. All constructs were confirmed by sequencing. Point mutants
were constructed by site-directed mutatgenesis of plasmids using the
Quickchange kit (Stratagene). Primers used in this study are described in
Table S4.
Cell Lines, Transfections, and Western Blot Analysis
HEK293T and HeLa cell lines (ATCC) were maintained in DMEM/5% Pen/
Strep/10% FBS at 37C in a CO2 incubator. Transfections were performed
with TransIT-LT1 transfection reagent (Mirus Bio) at a reagent:plasmid DNA
ratio of 3:1. For western blot analysis, cells were lysed in ice-cold NP40 doc
buffer (1% NP40, 0.2% sodiumdeoxycholate, 0.12 M NaCl, 20 mM Tris
pH 8.0) with protease inhibitors (Roche Complete Mini, EDTA-free tablets),
resolved by 12% SDS-PAGE, transferred to PVDF, and probed with anti-HA
(Santa Cruz Biotech) and actin (Sigma) antibodies.
Viral Infectivity Assays
Single-round HIV-1 infectivity assays were performed as previously described
(OhAinle et al., 2006; Yamashita and Emerman, 2004). All assays were per-
formed by transfection of 1.253 105 293T cells in 24-well plates with a 1:1 ratio
of pcDNA/APOBEC plasmid (250 ng) to BruLuc2 env- proviral plasmid
(250 ng). MusD and LINE-1 retroelement assays were performed essentially
as previously described (Esnault et al., 2002; Ribet et al., 2004). For MusD
assays, HeLa’s were plated at 2.5 3 105 cells/ml in 2 ml in 6-well plates and
triplicate wells transfected with 0.75 mg MusD plasmid and 0.75 mg APOBEC
expression plasmid. At day 3 post-transfection, cells were replated at 1.5 3
105 cells/ml in 2 ml of a 6-well dish. At day 4, cells were selected in G418+
media (0.4 mg/ml) and fresh G418+ media added every 2 days until single
colonies remained. For LINE-1 assays, HeLa’s were plated at 5 3 104 cells/
ml in 2 ml in a 6-well plate and transfected with 0.3 mg LINE-1 plasmid and
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HEK293T cells were plated at 2 3 105 cells/ml in 6 cm poly-L-lysine plates
(Becton Dickinson) and were transfected 1 day later with 5 mg pcDNA/
APOBEC plasmids. One day post-transfection, the pulse was initiated by incu-
bating cells in 1 ml starvation media (Met/Cys-free DMEM [Invitrogen]/5%
dialyzed FCS + L-glutamine). After 30 min, starvation media were removed
and 750 ml pulse media was added. Pulse media is starvation media plus
440 mCi EasyTag EXPRE35S35S Protein Label (PerkinElmer) per plate. Follow-
ing a 30 min pulse, pulse media were removed and 1 ml warm chase media
(Met/Cys-free DMEM + 5%FCS + 2 mM Met + 2 mM Cys) was added to all
plates. Cells were harvested at 0, 30 min, 1 hr, 2 hr, and 6 hr time points by
washing 13 in PBS and lysing cells directly in 500 ml ice-cold NP40 doc buffer
(1% NP40, 0.2% sodiumdeoxycholate, 0.12 M NaCl, 20 mM Tris, pH 8.0) with
protease inhibitors (Roche Complete Mini, EDTA-free tablets). Debris was
removed by spinning 5 min at 16,000 g at 4C and supernatants were frozen
at80C until use. HA-tagged APOBEC3H proteins were Immunoprecipitated
using protein G-sepharose beads (Zymed) conjugated to RAW HA.11 anti-
body. Lysates were precleared by incubating lysates with unconjugated beads
for 1 hr at 4C with rocking, and antibody was preconjugated with beads for
1 hr at 4C with rocking. Beads were washed twice in NP40 doc and spun
out for 2 min at 4000 g at 4C. 0.01% BSA was added to antibody-conjugated
beads which were incubated with precleared lysates for 2 hr at 4C with rock-
ing. Beads were spun out (2 min at 4000 g) and washed in a series of wash
buffers with protease inhibitors (Roche Mini, EDTA-free tablets) as follows:
RIPA (10 mM Tris pH7.5, 150 mM NaCl, 1% NP40, 1% sodiumdeoxycholate,
0.1% SDS), high salt buffer (2 M NaCl, 10 mM Tris pH7.4, 1% NP40, 0.5% so-
diumdeoxycholate), low salt buffer (0.5% NP40, 0.1% SDS in PBS), and RIPA.
Bead slurries were resuspended in 20 ml 23protein loading buffer (125mMTris
pH 6.8, 4% SDS, 20% glycerol and 10% b-mercaptoethanol) and boiled for
10 min, beads spun out at 16,000 g for 1 min, and supernatants used for
12% SDS-PAGE. Radioactivity was detected using a Typhoon Trio imager
(Amersham Biosciences) and quantitated using ImageQuantTL software
(Amersham Biosciences).
Immunofluoresence
HeLa cells plated onto coverslips in a 6-well dish at 2 3 105 cells/ml were
transfected the next day with 1.5 mg pcDNA/HA-APOBEC expression vectors.
Twenty-four hours post-transfection slips were fixed in 4% paraformaldehyde,
permeabilized in 0.3% Triton-X/PBS, and blocked in 10% FBS/PBS.
HA-tagged proteins were detected using RAWHA.11 antibody (Santa Cruz
Biotech) at a 1:100 dilution followed by anti-mouse-TexasRed conjugate
(Invitrogen). Nuclei were stained with DAPI in mounting media (Vectashield;
Vector Labs) and images were collected on an Olympus DeltaVision
microscope.
Ancestor Reconstruction
The human/chimpanzee ancestor APOBEC3H protein sequence was inferred
using the gorilla sequence as an outgroup. The human/chimpanzee ancestor
APOBEC3H cDNA was then constructed in vitro by site-directed mutagenesis
(QuikChange Site Directed Mutagenesis Kit—Stratagene) using the chimpan-
zee/human_A chimera as the template. The human ancestor APOBEC3H
protein was defined by determining all changes that are fixed in the human
population and reconstructed in vitro by site-directed mutagenesis using the
human hap I cDNA as a template.
Human APOBEC3H Genotyping
The human APOBEC3H coding sequence was amplified/sequenced from ge-
nomic DNA samples with the following primer pairs (see Table S4 for primer
sequences): Exon 1—Ex1_For/Ex1_Rev, Exons 2/3—Ex2&3_For/Ex2&3_Rev,
and Exon 4—Ex4_For/Ex4_Rev. A second round of sequencing was per-
formed to obtain missing data with the following primer pairs: Exon 2—
MO276/MO271, Exon 3—MO272/MO273, and Exon 4—MO274/MO275.
Human genomic DNA samples (Coriell) sequenced were African Pygmy
(GM10469–10473/GM10492–10494), South American (GM10965–10969),
Central American (GM10975/6/8 and 9), Caucasian (GM893, 946, 1310,
1805, 1806, 1814, 1953, 8428, 9948, and 14492), African South of the Sahara
(NA17341–17349), and African North of the Sahara (NA17378–17384).
Extended genotyping of the delN15 and R105G polymorphisms was per-258 Cell Host & Microbe 4, 249–259, September 11, 2008 ª2008 Elformed from the following Coriell samples: Han Chinese from Los Angeles
(NA17733-17747, 17749, 17752–17757, 17759, 17761), African American
(NA17102–17116, 17125, 17133–17140), and European American (NA06990,
07019, 07348, 07349, 10830, 10831, 10842–10845, 10848, 10850–10854,
10857, 10858, 10860, 10861, 12547, 12548, 12560, 17201). For the R105G
polymorphism, genomic DNA was amplified (Supermix; Invitrogen) with
primers JAK08 and JAK10 for 30 cycles (94C—30 s; 58C—30 s; 72C—
1.5 min) and PCR product diluted and directly sequenced. For the delN15
polymorphism, genomic DNA was amplified with primers MO285 and
MO286 with Taq for an initial denaturing for 5 min at 94C, followed by 30
cycles (94C—15 s; 58C—1 min) and a final 5 min extension at 72C. DNA
fragment analysis was performed on an Applied Biosystems 3730xl DNA An-
alyzer with a 36 cm capillary array and analyzed by GeneMapper 4.0 software
(Applied Biosystems) to detect the presence or absence of the 3 bp deletion.
Calculation of Hardy-Weinburg equilibrium (HWE) was used to assess geno-
typing accuracy; the data did not result in a significant rejection of HWE for
both the delN15 and R105G polymorphisms in each population.
Population Genetic Analysis
SNP data were input to PHASE 2.1.1 software (http://stephenslab.uchicago.
edu/software.html) and were used to infer phasing of haplotypes over five
iterations. Human haplotypes found at >10% frequency in the panel were
reconstructed by site-directed mutagenesis (Quickchange; Stratagene) of
human_A APOBEC3H and human_B APOBEC3H plasmids. Complete primer
sequences used in this study are found in Table S4. FST values were calculated
for each pairwise comparison using the following method of calculation:
(MSP  MSG)/[MSP + {nc  1)MSG] (Akey et al., 2002).
ACCESSION NUMBERS
GenBank accession numbers for the primate APOBEC3H sequences
described here are EU861357 through EU861361.
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